NeoTract Convenes Leading Urologists for Summit on Treating Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms

Three new UroLift® Centers of Excellence
Also Selected and Recognized

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet
needs in the field of urology, recently hosted more than 60 urologists
from around the country to review clinical data and share best practices
for using the UroLift® System to improve the care of
patients with enlarged prostate, or benign prostatic hyperplasia (BPH).
Highlights from the meeting included robust data presentations and the
designation of three new UroLift Centers of Excellence from Jamestown,
New York; Pittsburgh, Penn.; and Fullerton, Calif.

UroLift Centers of Excellence are recognized for completing extensive
training and demonstrating high success in advancing patient outcomes in
men with lower urinary tract symptoms. Currently, eight physician
practices across the nation have the experience and outcomes to have
earned this distinction.

“I am honored and humbled to have my practice named as a UroLift Center
of Excellence,” said Peter Walter, M.D., of Western New York Urology
Associates in Jamestown, NY. “After treating nearly 200 patients, I have
seen firsthand the dramatic benefits and quality of life improvements we
can offer to men who undergo the UroLift procedure. I believe it is
important to continue to share our personal clinical experiences and
data with peers so we can look to eventually eliminate the burden of

Over the course of the two-day summit, podium presentations reviewed
data and case presentations. Claus Roehrborn, M.D., professor and
chairman of the Department of Urology, UT Southwestern in Dallas, opened
the second day of talks with a new technology and clinical data review.
Dr. Roehrborn serves as co-principal investigator for the pivotal,
randomized L.I.F.T. IDE study.

“The UroLift clinical publication record is flawless,” said Dr.
Roehrborn. “Every patient treated under a clinical protocol appears in
at least one peer-reviewed publication. The outcomes from the numerous
studies are consistent, demonstrating rapid relief within two weeks and
sustained improvement in symptoms, quality of life and urinary flow
through four years.”1

“We are pleased with the large number of attendees at our first Summit,”
said Dave Amerson, president and CEO, NeoTract, Inc. “We’re very
fortunate to work with such a dedicated, talented group of physicians
who take time out of their busy schedules to learn from us and from each
other how to achieve the best possible outcomes for their patients.”

More than 37 million men in the United States are affected by BPH, which
occurs with advancing age when the prostate gland that surrounds the
male urethra becomes enlarged and begins to obstruct the urinary
system. Symptoms of BPH often include sleepless nights and urinary
problems, and can cause loss of productivity, depression and decreased
quality of life.

Medication is often the first-line therapy for enlarged prostate, but
relief can be inadequate and temporary. Side effects of medication
treatment can include sexual dysfunction, dizziness and headaches,
prompting many patients to quit using the drugs. For these patients, the
classic alternative is surgery that cuts, heats or removes prostate
tissue to open the blocked urethra.

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during a
minimally invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating, or
removing prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged prostate
receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.
Patients also experienced a significant improvement in quality of life.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System is available in the U.S.,
Europe, Australia and Canada. Learn more at

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at

1 Roehrborn, 2016 Urology Clinics


for NeoTract, Inc.
Nicole Osmer, 650-454-0505